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Abstract: Despite the development of many effective antihypertensive drugs, target blood 
pressures are reached in only a minority of patients in clinical practice. Poor adherence to drug 
therapy and the occurrence of side effects are among the main reasons commonly reported 
by patients and physicians to explain the poor results of actual antihypertensive therapies. 
The development of new effective antihypertensive agents with an improved tolerability 
proﬁ  le might help to partly overcome these problems. Lercanidipine is an effective dihydro-
pyridine calcium channel blocker of the third generation characterized by a long half-life and 
its lipophylicity. In contrast to ﬁ  rst-generation dihydropyridines, lercanidipine does not induce 
reﬂ  ex tachycardia and induces peripheral edema with a lower incidence. Recent data suggest 
that in addition to lowering blood pressure, lercanidipine might have some renal protective 
properties. In this review we shall discuss the problems of drug adherence in the management 
of hypertension with a special emphasis on lercanidipine.
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Introduction
Hypertension is one of the biggest health care problems of Western populations, 
as it is the major risk factor for strokes, acute coronary events and chronic kidney 
disease (Collins and Peto 1994). Its prevalence is high and its incidence continues to 
rise around the world. For example, data form the latest National Health Nutrition 
Examination Survey (NHANES), conducted between 1999 and 2000, have shown 
a prevalence of 28.7% in American adults, compared with 25% in a similar survey 
conducted between 1988 and 1991 (Hajjar et al 2003). In Switzerland, data from a 
recent stroke prevention campaign, which included 4458 persons (age 57.8 ± 15 years) 
visiting local shopping malls in 2001, showed a prevalence of hypertension of 47% 
(Nedeltchev et al 2005).
Research efforts have resulted in the development of many effective antihypertensive 
drugs. Clinical trials using these agents have lead to well deﬁ  ned indications and treat-
ment goals, in order to prevent irreversible organ damage due to hypertension. In recent 
years, an increasing number of patients are being treated with antihypertensives, 
although the percentage of treated hypertensive patients remains largely insufﬁ  cient 
and is estimated at only 30% to 45% (MMWR 2005).
The most important aspect of pharmacological treatment of hypertension is to obtain 
a sustained normalization of blood pressure, irrespective of the drug class used. Since 
hypertension is a chronic, usually asymptomatic, disorder needing life-long treatment, 
thorough adherence to medication is important. Unfortunately, non-compliance is a 
frequent issue, its prevalence varying from 17% to 60% depending on the deﬁ  nition 
used and the methods applied to detect non-compliance (Joint National Committee 
1997; Caro et al 1999; Nuesch et al 2001). The economic burden of non-adherence is 
important, not to mention the clinical consequences for patients.Vascular Health and Risk Management 2008:4(6) 1160
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Several factors play a role in medication adherence, but 
amongst the key determinants are the complexity of the 
medication regimen and the side effect proﬁ  le of the drug used. 
In this review, the problems of adherence in treating hyperten-
sion and their relationship with the side effect proﬁ  le of several 
drug classes will be discussed with a special emphasis on the 
third-generation calcium antagonist lercanidipine.
Drug adherence and the treatment 
of hypertension
Deﬁ  nitions and detection
Many different deﬁ  nitions of compliance are used in the 
literature, which makes comparison of studies sometimes 
difficult. Besides, some argue that “compliance” has 
nowadays a somewhat negative connotation, merely imply-
ing “obedience to physicians orders”. Therefore, some 
authors have proposed using the term adherence rather than 
compliance (Loghman-Adham 2003). Medication adherence 
can be deﬁ  ned as “the extent to which a patient’s behavior, 
with respect to taking medication, corresponds with agreed 
recommendations from healthcare providers” (WHO 2003). 
Adherence can be divided into two main components: 
persistence and execution. Persistence is deﬁ  ned as the time 
from the ﬁ  rst to the last dose taken, eg, the time during which 
the drug has been taken, whereas the execution refers to the 
comparison between the prescribed drug dosing regimen 
and the patient’s drug history while on treatment. The latter 
deﬁ  nition includes dose omissions (missed doses) and the 
so-called “drug holidays” (3 or more days without drug 
intake) (Urquhart et al 2005). While non-persistence can be 
identiﬁ  ed, for example, by the failure of patients to collect a 
second prescription in a pharmacy registry, it is very difﬁ  cult 
to diagnose poor execution with traditional methods such as 
patient diaries and measurements of plasma drug concentra-
tions, which in general tend to overestimate adherence (Pullar 
et al 1989; Waeber et al 1999). More insights into speciﬁ  c 
drug intake patterns of antihypertensives have been gained 
by using electronic pill box monitoring (Medical Event 
Monitoring System, MEMS®), which enables monitoring of 
the execution on a daily basis by recording the time of each 
opening of the pill container (Kruse and Weber 1990). Several 
lessons have been learned from this device. First, adherence 
is a dynamic process that ﬂ  uctuates in time, meaning that 
phases of good adherence can alternate with phases of poor 
compliance in the same patient. For example, patients tend to 
be more compliant around the time of a follow-up visit; this 
has led to the term “white coat compliance”. Second, persis-
tence decreases progressively over time, the largest decrease 
occurring during the ﬁ  rst 6 to 8 months of therapy (Burnier 
et al 2003). Third, patients who have poor execution (omit-
ting doses, drug holidays, variability in hour of intake) are at 
highest risk of quitting early, thus leading to poor persistence. 
Fourth, “morning takers” are more likely to have a good 
execution than “evening takers” (Vrijens et al 2008).
These ﬁ  ndings have led Vrijens et al to propose some 
practical recommendations: whenever possible, drugs should 
be taken in the morning and one should try to prescribe drugs 
that sustain full pharmacological action for one or two dosing 
cycles after omitted doses.
Adherence according to antihypertensive 
drug classes
Several studies have compared medication adherence of 
different drug classes. The largest trials are outlined in 
Table 1. Most of these data are derived from prescription 
databases that give insight into persistence but not in execu-
tion. Despite differences in design, these studies show the 
same tendency, namely that angiotensin (AT)-II blockers 
and angiotensin converting enzyme (ACE)-inhibitors have 
a slightly higher persistence than, respectively, calcium 
antagonists and beta blockers, and that persistence with 
diuretics is the lowest.
Table 1 Studies comparing adherence rates of different antihypertensive drugs
Studya n Outcome (persistence) AT -II blockers ACE-inhibitors Calcium 
antagonists
Beta-blockers Diuretics
Blooms 1998 21,723 1-year persistence 64% 58% 50% 43% 38%
Caro 1999 22,918 4.5-year persistence neb 53% 47% 49% 40%
Morgan 2004 82,824 1-year persistence 56% 56% 52% 54% 49%
Polluzzi 2005 6,043 3-year persistence* 52% 43% 39% 47% 23%
Simons 2008 48,690 33-month persistence 84% 84% 72% ne ne
aAll theses studies are retrospective.
bnot evaluated.Vascular Health and Risk Management 2008:4(6) 1161
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This drug class difference in treatment persistence has 
raised some questions. Confounding factors could have 
influenced the results. However, correction for several 
factors including age, gender, number of physician visits or 
hospital admissions did not change the results. According 
to a questionnaire-based survey among primary care physi-
cians in Italy, the main reasons for drug discontinuation are 
treatment failure and side effects (Ambrosioni et al 2000). 
A similar observation was made in Switzerland where lack 
of efﬁ  cacy and the side effect proﬁ  le were identiﬁ  ed as the 
main determinants of non-persistence (Burnier et al 2005). 
Large prospective clinical trials have also shown differences 
in discontinuation rates in favor of ACE-inhibitors and AT-II 
blockers. On average, drug interruptions occur in 15% of 
patients taking ACE-inhibitors and in 20% of patients taking 
beta blockers, diuretics or calcium antagonists; among the 
main reasons for drug interruption were once again side 
effects (Shulman et al 1982; Croog et al 1986; Jones et al 
1995). These trials, however, were not designed to compare 
persistence rates but compared clinical endpoints such as 
stroke and other cardiovascular events.
Finally, one Italian prospective study examining 
persistence of antihypertensive treatment in 347 patients 
confirms the findings of Table 1. In this study, mild to 
moderate hypertensive patients were randomly allocated to 
monotherapy with either ACE-inhibitors, AT-II blockers, 
calcium antagonists, beta blockers or diuretics, and followed 
for 24 months (Veronesi et al 2007). Persistence of treatment 
was highest among ACE-inhibitors (64.5%) and ATII-blockers 
(68.5%), as compared to calcium-antagonists (51.6%), 
beta blockers (44.8%) and diuretics (34.4%). The main 
reason for drug interruption was the occurrence of side 
effects. Age   65 years (odds ratio [OR]: 1.27) and female 
sex (OR 1.08) were associated with higher persistence. 
ACE-inhibitors and AT-II inhibitors are well known for their 
favorable side effect proﬁ  le, and a further discussion of these 
drug categories is beyond the scope of this article. Calcium 
antagonists show slightly lower persistence rates (Table 1). 
Interestingly, in the study by Veronesi et al patients treated 
with lercanidipine were more likely to persist than patients 
taking other dihydropyridines (59.3% vs 46.6%; OR: 1.43), 
which brings us to discuss this compound more in detail.
Lercanidipine, a well tolerated 
calcium channel blocker
Calcium antagonists represent a heterogeneous group of 
agents, including mainly the dihydropyridines (DHP), 
verapamil and diltiazem. Lercanidipine is a third-generation 
calcium antagonist with an improved side effect proﬁ  le, which 
makes it – in terms of adherence – an interesting compound, 
alone or in combination with other antihypertensives in the 
treatment of hypertension.
Pharmacology
Lercanidipine is a member of the 1,4-DHP calcium channel 
blocker class which blocks the inﬂ  ux of calcium via competi-
tive antagonism of L-type calcium channels, thus leading to 
smooth muscle relaxation and vasodilatation (Herbette et al 
1997). Lercanidipine is almost completely absorbed from 
the gastrointestinal tract and reaches its maximal plasma 
concentration after 1 to 3 hours. It is highly bound to proteins 
(  98%) and has a distribution volume of 2 to 2.5 L/kg (Bang 
et al 2003). Lercanidipine is highly lipophylic: hence the 
drug has a better penetration in hydrophobic cell membranes 
than other DHPs and penetrates even in smooth muscle cells 
surrounded by cholesterol-rich plaques (Herbette et al 1997). 
This might explain its high efﬁ  ciency in a wide range of 
patients, including patients with a high cardiovascular risk 
proﬁ  le and diffuse atherosclerosis.
Another property of lercanidipine is a long duration of 
action, resulting in 24-hour blood pressure control after 
a single dose (Beckey et al 2007) despite a short plasma 
half-life. Once again, its lipophylic proﬁ  le explains this 
apparent discrepancy, as lercanidipine is quickly stored in 
the hydrophobic component of the cell membrane layer. 
Lercanidipine induces a slow-onset, prolonged smooth muscle 
relaxation, resulting in peripheral and coronary vasodilata-
tion and thus steady lowering of the blood pressure without 
important reﬂ  ex tachycardia (Sironi et al 1996). Lercanidipine 
is metabolized by CYP3A4; plasma concentrations are thus 
inﬂ  uenced by inducers or inhibitors of 3A4 such as cimetidine, 
ketoconazole and grapefruit juice.
Tolerability proﬁ  le of lercanidipine
In contrast to beta blockers and diuretics, which may worsen 
insulin resistance (Mason et al 2005) and increase total 
cholesterol, low density lipoprotein and total glyceride levels 
(Weir and Moser 2000) and hence the risk of diabetes (Gress 
et al 2000), calcium antagonists are metabolically neutral. In 
the ASCOT trial, for example, the combination of atenolol/
ﬂ  umethazine was associated with a signiﬁ  cantly higher risk 
of new onset diabetes compared with the group treated with 
perindopril and amlodipine (Dahlöf et al 2005), especially 
when fasting plasma glucose was   5 mmol/L (Gupta et al 
2008). The widespread use of calcium antagonists in clinical 
practice has been limited, however, by one frequent side Vascular Health and Risk Management 2008:4(6) 1162
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effect – peripheral edema. Thus, in ASCOT, for example, 
peripheral edema developed in 23% of treated patients, and 
was the leading cause of interruption of amlodipine.
The main advantage of lercanidipine is that it induces less 
peripheral edema than other DHPs. On average, peripheral 
edema develops in 0.6% to 9% of treated patients (at the 
dose of 10 mg daily), which is considerably lower than 
the 23% reported in the ASCOT trial (Table 2). Obser-
vational studies have shown that in patients previously 
treated with another DHP, switching from a ﬁ  rst-generation 
DHP to lercanidipine reduces the likelihood of developing 
peripheral edema by approximately 50% (Borghi et al 
2003). In an observational study of Burnier et al (2007), this 
likelihood was even lower. This observational, prospective, 
phase IV study investigated the efficacy and tolerabil-
ity of lercanidipine as prescribed in private practices in 
Switzerland. Lercanidipine was prescribed as monotherapy 
(n = 683), or as step-on therapy (n = 844), or as substitution 
for another drug (n = 672) to hypertensive patients (mean 
age 58–69 years; 10%–22% diabetics); doses were uptitrated 
to 20 mg in case of insufﬁ  cient blood pressure control after 
4 weeks. Of the 182 patients that started lercanidipine because 
of peripheral edema with another calcium antagonist, only 
10 experienced edema on lercanidipine. Moreover, the 
persistence was very high at 98%–99% and 63% reached 
the target blood pressure ( 140/90 mmHg) (Burnier et al 
2007). An even larger study including 9059 Spanish patients 
(ELYPSE study, Table 2), found similar results: the overall 
incidence of adverse events was 6.5%, of which 2.9% was 
headache, 11% ﬂ  ushing, 0.6% palpitations and only 1.2% 
ankle edema (Barrios et al 2002). Persistence was   99%, 
although the follow-up period was, again, rather short.
The highest rate of peripheral edema (39.7%) was 
found in the TOLERANCE study (Barrios et al 2008). This 
observational study included 650 hypertensive patients on 
lercanidipine or another DHP (amlodipine or nifedipine GITS) 
who were uptitrated from a low dose ( 10 mg, 5 mg and 30 mg 
respectively) to a high dose (20 mg, 10 mg and 60 mg) of the 
mentioned drugs. Two explanations might explain the high 
rate of peripheral edema in this study. Firstly, the peripheral 
edema was reported by the patient and might have been over-
estimated. Secondly, the dose of lercanidipine used was higher 
than in the other studies. Finally, the peripheral edema did not 
lead to drug interruption, as illustrated by high adherence rates 
(93.9 vs 93.7% in the amlodipine/nifedipine group).
All these studies were observational, non-randomized 
studies, and thus selection bias cannot be excluded and the 
ﬁ  ndings should be interpreted with caution. However, the 
only prospective, double-blind randomized trial – performed 
in stage I or II hypertensive elderly patients (  60 years) – 
also found signiﬁ  cantly more edema in the amlodipine group 
than in the lercanidipine or lacidipine group (COHORT) 
(Degiorgio et al 1999).
Why lercanidpine leads to less leg edema remains 
unknown. It is generally believed that DHPs induce 
an increase in the intra-capillary hydrostatic pressure 
due to arteriolar vasodilatation, and that reflex sympa-
thetic activation avoids adequate post-capillary venous 
vasodilatation (Angelico et al 1999). Lercanidipine induces 
less sympathetic activation and thus less peripheral edema 
than other DHPs (Fogari et al 2003). Although a single-blind 
cross-over study in 22 male hypertensive patients conﬁ  rmed 
the difference in edema-forming potential as measured by 
the water displacement method, this study did not ﬁ  nd a 
difference in interference with postural vasoconstrictor 
mechanisms between amlodipine (10 mg) and lercanidipine 
(20 mg) (Pedrinelli et al 2003).
Thanks to its slow onset of action, reﬂ  ex tachycardia 
is rare, as well as ﬂ  ushing and acute hypotension. This 
was illustrated by an analysis of 14 placebo-controlled, 
Table 2 Large trials having evalauted the tolerability and efﬁ  cacy of lercanidipine therapy in daily clinical practice
Study (year)a n Type Medication Duration Peripheral edema (%)
LAURA study 
2006
3175 Open label, 
non-comparative
Lercanidipine 10–20 mg/day 6 months 5.1
TOLERANCE 
study 2008
650 Observational Lercanidipine 20 mg vs amlodipine 
10 mg or nifedipine GITS 60 mg
2 months 39.7 vs 57.3
Burnier 2007 2199 Observational, 
non-interventional
Lercanidipine 10 mg/20 mg; mono, 
step on, or substitution therapy
2 months 0.6–3
ELYPSE 2002 9059 Observational Lercanidipine 10 mg 3 months 1.2
COHORT 
2002
828 Prospective, randomized, 
double blind
Lercanidipine 10 mg vs amlodipine 
5 mg vs lacidipine 2 mg
12 months 9 vs 19 vs 4
aStudies were selected by performing a Pubmed query with “lercanidipine”, “adherence”, “compliance” and “tolerability” as search terms.Vascular Health and Risk Management 2008:4(6) 1163
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double-blind trials including 1850 patients: 2.1% of patients 
presented tachycardia, 1.7% palpitations and 2.0% ﬂ  ushing 
(Hollenberg 2002). Its vasodilatatory properties and its lack 
of sympathetic activation probably explain its anti-anginal 
actions (Sasaki et al 2005). This anti-ischemic effect was 
evaluated in a study including 23 patients with stable 
angina who performed bicycle exercise testing and simul-
taneous ambulatory radionuclide testing to estimate the left 
ventricular function, before and after the introduction of 
lercanidipine 10 mg to 20 mg. Lercanidipine increased in a 
dose-dependent way the time to onset of ST depression and 
improved total exercise duration, without changing heart rate 
with respect to pretreatment level (Acanfora et al 2004).
Clinical efﬁ  cacy of lercanidipine
Several studies have demonstrated the efﬁ  cacy of lercanidipine 
monotherapy in the treatment of hypertension. Reductions 
of systolic and diastolic blood pressure of respectively 19 to 
26 mmHg and 13 to 15 mmHg have been reported with 
lercanidipine, and non-inferiority studies have shown that 
lercanidipine is as effective in lowering blood pressure as, for 
example, atenolol, hydrochlorothiazide, captopril, telmisartan 
and amlodipine. Calcium antagonists are particularly suitable 
for patients with the Raynaud phenomenon or angina pectoris 
and they are effective in stroke prevention (Basile 2004; 
Verdecchia et al 2005). For a detailed review of these studies, 
we refer the reader to the excellent article that has been 
published previously in this journal (Borghi 2005). Since 
then, clinical studies have been performed to investigate the 
role of lercanidipine in combination therapy and its potential 
renal protective properties.
Use of lercanidipine in combination 
therapies
The majority of hypertensive patients need at least two or 
three drugs to control their blood pressure, and lifelong treat-
ment is necessary to prevent organ damage (Mancia et al 
2007). Calcium antagonists are interesting drugs for combina-
tion therapy because of their mentioned favorable side effect 
proﬁ  le and metabolic neutrality. They are effective when 
used in combination with ACE-inhibitors, AT-II blockers, 
thiazide diuretics and beta blockers (Mancia et al 2007) and 
since the results of the ASCOT trial combinations of calcium 
channel blockers and blockers of the renin-angiotensin 
system have become increasingly popular. Lercanidipine 
has received special interest thanks to its mild side effect 
proﬁ  le, and the performed combination therapy studies 
are mentioned in Table 3. As can be seen, these studies had 
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a rather short follow-up period, enrolled a relatively small 
number of patients and were often not blinded. Thus, more 
studies are needed to determine the place of lercanidipine in 
the combination therapy of hypertension.
Lercanidipine in renal protection
Studies examining the role of calcium antagonists for renal 
protection and to reduce proteinuria have provided conﬂ  icting 
results. Some studies, such as the SYST-EUR trial and the 
ALLHAT study, showed results in favor of, respectively, 
nitrendipine and amlodipine compared with placebo 
(SYST-EUR) or diuretics (ALLHAT) (Voyaki et al 2001; 
the ALLHAT ofﬁ  cers 2002). However, other studies, such 
as the African American Study of Kidney Disease (AASK), 
were discouraging. In this study, amlodipine signiﬁ  cantly 
increased proteinuria compared with metoprolol or ramipril 
(Douglas and Agodoa 2003).
These conﬂ  icting results may partly be explained by 
the heterogeneity of calcium antagonists as a group and 
particularly their different impact on renal hemodynamics. 
Non-DHPs as well as DHPs mainly dilate the afferent 
preglomerular arterioles, thus resulting in relatively 
unchanged or increased renal plasma ﬂ  ow (RPF) but higher 
glomerular ﬁ  ltration rate (GFR) which might result in raised 
intra-glomerular capillary pressure (Arima et al 1996). 
However, a growing body of evidence suggests that some 
DHPs also vasodilate the efferent, post-glomerular vessels 
and thus lower intra-glomerular pressure. This has been 
reported, for example, when manidipine, a third-generation 
calcium antagonist, was administered to spontaneous hyper-
tensive rats (SHR). Upon administration of manidipine, 
RPF increased more than GFR, resulting in decreased 
ﬁ  ltration fraction (Takabatake et al 1993). Lercanidipine 
also possesses post-glomerular vasodilatory capacities. This 
was shown by Sabbatini et al (2000), who treated SHR for 
12 weeks with lercanidipine and found dilatation of efferent 
as well as afferent arterioles.
Few clinical studies have examined the role of lercanidipine 
in patients with chronic kidney damage and/or proteinuria. 
The ZAFRA study (Zanidip en Función Renal Alterada) 
is the largest study so far that has addressed this subject 
(Robles et al 2005). This open label study included 203 
patients (20% diabetics) with a creatinine clearance below 
70 mL/min and a higher-than-recommended blood pressure, 
despite therapy with ACE-inhibitors (63.4%) or AT-II blockers 
(36.6%). Lercanidipine 10 mg was added and patients were 
followed for 6 months. Systolic blood pressure decreased from 
162 ± 16.6 to 131.6 ± 11.6 mmHg, diastolic blood pressure 
decreased from 93.2 ± 8.3 to 78.2 ± 6.4 mmHg, creatinine 
clearance improved from 41.8 ± 16.0 to 45.8 ± 18.0 mL/min 
and proteinuria (as measured by 24-hour urine collection) 
decreased from 3.5 ± 3.2 to 2.8 ± 2.8 g/day. No patient devel-
oped peripheral edema and only one progressed to end stage 
renal failure. This open label study underlined the safety and 
antihypertensive potential of lercanidipine in patients with 
chronic renal failure (CRF). However, the study was not 
designed to demonstrate eventual blood pressure- independent 
renoprotective properties of lercanidipine, and further studies 
are needed to determine its role and properties in CRF patients. 
In the meantime, a ﬁ  xed-dose formulation of lercanidipine 
10 mg/enalapril 10 mg is approved in Germany for the treat-
ment of hypertension. A 12-week, randomized, double-blind 
trial showed effective blood pressure lowering and high 
tolerability of this combination, with  1.5% of patients 
developing peripheral edema (Hair et al 2007).
Conclusions
Hypertension is an asymptomatic disease needing lifelong 
lifestyle modifications and drug therapy. Excellent 
adherence to drug therapy is necessary to achieve strict 
blood pressure control. The use of antihypertensive agents 
with a high efﬁ  cacy in a broad range of patient categories 
and a favorable tolerability proﬁ  le is important to improve 
adherence. Lercanidipine is a third-generation calcium 
antagonist with a proven antihypertensive efficacy in 
monotherapy and combination therapy, although many 
studies were non-randomized, open label trials. Its main 
advantage over ﬁ  rst- and second-generation DHPs is its 
lower incidence of adverse effects, in particular peripheral 
edema. Future clinical experience trials will demonstrate 
whether lercanidipine has indeed renoprotective properties, 
as suggested by animal studies and small clinical trials. 
Presently, the development of drugs such as lercanidipine 
could represent an important step to enhance persistence to 
therapy in hypertension.
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